A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Conditions

• Atopic Dermatitis
• Atopic Dermatitis Eczema
• Eczema

Eligibility Criteria

Sex

ALL

Age

18 Years - 74 Years

Healthy Volunteers

Not accepted

Interventions

• IMG-007 — DRUG
  Participants will receive IMG-007 subcutaneously.
• Placebo — DRUG
  Participants will receive a placebo subcutaneously.

Study Details

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Key Dates

Start date

Jun 17, 2025

Status verified

May 2026

Primary completion

Dec 31, 2027

Completion

Aug 31, 2028

Study Design

Enrollment

405 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: IMG-007 Dose 1
  Subcutaneous injection as per protocol.
• Experimental: IMG-007 Dose 2
  Subcutaneous injection as per protocol.
• Experimental: IMG-007 Dose 3
  Subcutaneous injection as per protocol.
• Experimental: IMG-007 Dose 4
  Subcutaneous injection as per protocol.
• Experimental: IMG-007 Dose 5
  Subcutaneous injection as per protocol.
• Experimental: IMG-007 Dose 6
  Subcutaneous injection as per protocol.
• Experimental: IMG-007 Dose 7
  Subcutaneous injection as per protocol.
• Placebo Comparator: Placebo Crossover Dose 1
  Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol.
• Placebo Comparator: Placebo Crossover Dose 2
  Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol.

Primary Outcome Measure

Mean percent change from baseline in EASI at Week 24 [ Time Frame: Baseline, Week 24 ]

Central Contacts

• ADAPTIVE Study Lead
  (858) 345-6927
  [email protected]

Locations (16)

Find similar trials in Lancaster, CA

Related Studies

• Skin Microbial Ecology in Atopic Dermatitis
  Recruiting · University of Rochester · Rochester, New York
• Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
  PHASE4 · Recruiting · Northwestern University · Chicago, Illinois
• A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
  Recruiting · Pfizer · New York, New York
• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
  PHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama